SYNB1618 demonstrated proof of concept with meaningful reduction of plasma phenylalanine (Phe) levels in an interim analysis of the Phase 2 SynPheny-1 Study --
-- SYNB1934, an optimized strain of SYNB1618, demonstrated two-fold increase in biomarkers of Phe metabolism compared to SYNB1618 --
-- Phase 2 SynPheny-1 study will incorporate SYNB1934. Company to prepare to start Phase 3 program with the most promising strain in Phenylketonuria (PKU) in 2022 --
-- Conference call and webcast to discuss results at 8:30 AM --
Conference Call & Webcast Information
Synlogic will host a conference call and live webcast at 8:30 a.m. ET today, Monday, September 20, 2021. To access the live webcast, please visit the "Event Calendar" page within the Investors and Media section of the Synlogic website. Investors may listen to the call by dialing +1 (844) 815-2882 from locations in the United States or +1 (213) 660-0926 from outside the United States. The conference ID number is 1154745. A replay will be available for 30 days on the Investors and Media section of the Synlogic website.
https://finance.yahoo.com/news/synlogic-announces-positive-phase-2-103000006.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.